[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gossamer Bio Inc (GOSS)

Gossamer Bio Inc (GOSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,136
  • Shares Outstanding, K 234,696
  • Annual Sales, $ 48,470 K
  • Annual Income, $ -170,370 K
  • EBIT $ -179 M
  • EBITDA $ -184 M
  • 60-Month Beta 2.04
  • Price/Sales 0.97
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.79
  • Most Recent Earnings $-0.20 on 05/15/26
  • Next Earnings Date 08/04/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 366.59% (+98.73%)
  • Historical Volatility 156.63%
  • IV Percentile 80%
  • IV Rank 45.69%
  • IV High 724.66% on 07/16/26
  • IV Low 65.36% on 08/20/25
  • Expected Move (DTE 23) 0.3400 (164.49%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 282
  • Volume Avg (30-Day) 392
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 66,863
  • Open Int (30-Day) 64,528
  • Expected Range 0.0000 to 0.5467

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 3
  • High Estimate $-0.04
  • Low Estimate $-0.12
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +52.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1138 +81.63%
on 07/14/26
0.2682 -22.93%
on 07/28/26
+0.0427 (+26.04%)
since 06/29/26
3-Month
0.1138 +81.63%
on 07/14/26
0.3799 -45.59%
on 05/04/26
-0.1429 (-40.88%)
since 04/29/26
52-Week
0.1138 +81.63%
on 07/14/26
3.8700 -94.66%
on 12/15/25
-1.7533 (-89.45%)
since 07/29/25

Most Recent Stories

More News
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH – – Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning...

GOSS : 0.2067 (+0.78%)
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial...

GOSS : 0.2067 (+0.78%)
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial...

GOSS : 0.2067 (+0.78%)
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial...

GOSS : 0.2067 (+0.78%)
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial...

GOSS : 0.2067 (+0.78%)
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their...

GOSS : 0.2067 (+0.78%)
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: ...

GOSS : 0.2067 (+0.78%)
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

SAN FRANCISCO , June 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. ( NASDAQ: GOSS ) and an executive, seeking to represent investors who...

GOSS : 0.2067 (+0.78%)
Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS

LOS ANGELES , June 1, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS ) violations...

GOSS : 0.2067 (+0.78%)
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , June 1, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer"...

GOSS : 0.2067 (+0.78%)

Business Summary

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology...

See More

Key Turning Points

3rd Resistance Point 0.2483
2nd Resistance Point 0.2301
1st Resistance Point 0.2184
Last Price 0.2067
1st Support Level 0.1885
2nd Support Level 0.1703
3rd Support Level 0.1586

See More

52-Week High 3.8700
Fibonacci 61.8% 2.4351
Fibonacci 50% 1.9919
Fibonacci 38.2% 1.5487
Last Price 0.2067
52-Week Low 0.1138

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.